GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

• Susan E. Alters ,

  * E-mail: salters@amunix.com

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Bryant McLaughlin,

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Benjamin Spink,

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Tigran Lachinyan,

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Chia-wei Wang,

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Vladimir Podust,

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Volker Schellenberger,

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯
• Willem P. C. Stemmer

  Affiliation Amunix Inc., Mountain View, California, United States of America

  ⨯